-
Products are supplied strictly for laboratory and scientific research — not for human or veterinary use.
Research & Education
GLP-1 pregnancy questions require special caution. Weight loss offers no benefit during pregnancy and may cause fetal harm; current FDA labeling directs discontinuation of weight-management products when pregnancy is recognized.
Current Wegovy and Zepbound prescribing information states that the products should be discontinued when pregnancy is recognized. The labels explain that weight loss is not recommended during pregnancy and describe limitations in human data alongside findings from animal studies.
Drug elimination is not immediate, and recommendations differ by product. For semaglutide, labeling advises stopping at least two months before a planned pregnancy because of its long half-life. A prescriber should interpret the current label and individual circumstances.
Zepbound delays gastric emptying and may reduce the effectiveness of oral hormonal contraceptives. Its label advises switching to a non-oral method or adding a barrier method for four weeks after initiation and for four weeks after each dose escalation. This requires clinician counseling.
Do not rely on internet reassurance or panic. Contact the prescribing clinician or obstetric-care professional, who can review timing, dose, health conditions and current evidence. Observational data cannot prove safety for an individual pregnancy.
No. Changes in weight or metabolic health may affect reproductive patterns, but approved indications and evidence must not be misrepresented.
That decision involves postpartum health, breastfeeding considerations and the current product label.
Product-specific labeling and clinician guidance are essential.
